Clinical Trials
294 trialsMountainTAP-29
Bristol-Myers Squibb
A Study of PHN-012 in Patients With Advanced Solid Tumors
Pheon Therapeutics
Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer
Merus B.V.
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Blueprint Medicines Corporation
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Amgen
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Pfizer
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
Pfizer
Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer
SystImmune Inc.
SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
Sound Pharmaceuticals, Incorporated
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Revolution Medicines, Inc.
SUNRAY-01
Eli Lilly and Company
NEOLA
AstraZeneca
ALINEAR
AstraZeneca
Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.
Pfizer
KontRASt-02
Novartis
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Boehringer Ingelheim
Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study
AstraZeneca
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
Genmab
ALKAZAR
Nuvalent Inc.
DIASTAG
AstraZeneca
ARC-10
Arcus Biosciences, Inc.
VELOCITY-Lung
Gilead Sciences
A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea
Novartis
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
BioNTech SE
MK-3475-01E
Merck Sharp & Dohme LLC
CASCADE
AstraZeneca
REVIVE
AstraZeneca
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Revolution Medicines, Inc.
ANASTASIA
AstraZeneca
A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer.
Pfizer
RASolve 301
Revolution Medicines, Inc.
VISUALIZE-2
Vergent Bioscience, Inc.
REZILIENT4
Taiho Oncology, Inc.
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Bristol-Myers Squibb
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
TRIDENT-1
Turning Point Therapeutics, Inc.
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Seagen Inc.
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
GlaxoSmithKline
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
EVEREST-2
A2 Biotherapeutics Inc.
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
MK-3475-01G
Merck Sharp & Dohme LLC
MK-3475-01I
Merck Sharp & Dohme LLC
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Hoffmann-La Roche
MK-3475-01F
Merck Sharp & Dohme LLC
NeoCOAST-2
AstraZeneca
CREATE
AstraZeneca
KANNON
Avistone Biotechnology Co., Ltd.
TroFuse-019
Merck Sharp & Dohme LLC
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
BeOne Medicines